Molecular Targeting, Bexion to develop molecular imaging product
Molecular Targeting Technologies has agreed to collaborate with Bexion Pharmaceuticals to develop a new nanovesicle for molecular imaging of tumors.
Bexion of Cincinnati said it has demonstrated that specific versions of the nanovesicles can be used to selectively target a broad range of tumors (both solid and hematologic). Specific formulations have also demonstrated the potential for treatment of a wide range of human cancers, including gliomas, prostate and pancreatic cancer, the company said.
“We will develop dual modality diagnostics using this technology. The ability to visualize the tumor by two imaging modalities offers a new approach for monitoring and accurate resection of tumors,” said Brian Gray, MD, vice president of research at the West Chester, Pa.-based Molecular Targeting.
Bexion of Cincinnati said it has demonstrated that specific versions of the nanovesicles can be used to selectively target a broad range of tumors (both solid and hematologic). Specific formulations have also demonstrated the potential for treatment of a wide range of human cancers, including gliomas, prostate and pancreatic cancer, the company said.
“We will develop dual modality diagnostics using this technology. The ability to visualize the tumor by two imaging modalities offers a new approach for monitoring and accurate resection of tumors,” said Brian Gray, MD, vice president of research at the West Chester, Pa.-based Molecular Targeting.